Skip to content
Study details
Enrolling now

A Study of NN3201 for Advanced Cancer

Novelty Nobility, Inc.
NCT IDNCT06805825ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

67

Study length

about 2.9 years

Ages

18+

Locations

5 sites in MI, OH, OR +2

What this study is about

Researchers are testing a new drug called NN3201 in people with advanced or metastatic solid tumors that have c-Kit. The goal is to see if the drug is safe and well-tolerated. The trial will involve two phases: a dose escalation phase to determine the maximum tolerated dose, followed by an expansion phase to assess the drug's effectiveness.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take NN3201

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Incidence of Adverse Events:

Secondary: Pharmacokinetics (PK) of NN3201

Body systems

Oncology, Gastroenterology